Skip to main content

Table 1 Baseline characteristics by initial dosing strategy of thromboprophylaxis

From: Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients

  Total (n = 152) Initial dosing strategy of thromboprophylaxis p-valued
Low dosea (n = 67) Medium doseb (n = 48) High dosec (n = 37)
Age, years 61 (52–69) 63 (52–71) 58 (51–66) 63 (54–70) 0.39
Male sex, No. (%) 125 (82.2) 59 (88.1) 35 (72.9) 31 (83.8) 0.12
BMI, kg/m2 28.4 (25.8–32.5) 27.7 (25.5–30.6) 29.4 (26.5–34.3) 28.4 (25.1–32.8) 0.10
 BMI ≥ 30 kg/m2, No. (%) 58 (39.7) 20 (31.8) 23 (48.9) 15 (41.7) 0.18
Tobacco use
 Never, No. (%) 79 (52.0) 32 (47.8) 28 (58.3) 19 (51.4) 0.53
 Former smoker, No. (%) 49 (32.2) 24 (35.8) 12 (25.0) 13 (35.1) 0.40
 Current smoker, No. (%) 7 (4.6) 3 (4.5) 3 (6.3) 1 (2.7) 0.79
Comorbidities
 Hypertension, No. (%) 69 (45.4) 32 (47.8) 20 (41.7) 17 (46.0) 0.83
 Diabetes without complications, No. (%) 19 (12.5) 8 (11.9) 6 (12.5) 5 (13.5) 0.99
 Diabetes with complications, No. (%) 6 (4.0) 4 (6.0) 0 (0.0) 2 (5.4) 0.24
 Obstructive pulmonary disease, No. (%) 30 (19.7) 12 (17.9) 11 (22.9) 7 (18.9) 0.81
 Ischemic heart disease, No. (%) 12 (7.9) 6 (9.0) 2 (4.2) 4 (10.8) 0.51
 Renal failure, No. (%) 9 (5.9) 6 (9.0) 3 (6.3) 0 (0.0) 0.17
 Liver disease, No. (%) 3 (2.0) 1 (1.5) 1 (2.1) 1 (2.7) 0.99
 Immunosuppression, No. (%) 8 (5.3) 5 (7.5) 1 (2.1) 2 (5.4) 0.53
 Malignancy, No. (%) 9 (5.9) 6 (9.0) 1 (2.1) 2 (5.4) 0.34
 Psychiatric disorder, No. (%) 26 (17.1) 11 (16.4) 9 (18.8) 6 (16.2) 0.96
Chronic medication
 Vitamin K antagonist, No. (%) 1 (0.7) 0 (0.0) 0 (0.0) 1 (2.7) 0.24
 Direct oral anticoagulation, No. (%) 8 (5.3) 3 (4.5) 1 (2.1) 4 (10.8) 0.24
 Antiplatelet therapy, No. (%) 15 (9.9) 9 (13.4) 3 (6.3) 3 (8.1) 0.47
Duration of symptoms prior to admission
 Hospital admission, days 9 (7–12) 9 (6–13) 8 (6–12) 10 (7–14) 0.18
 ICU admission, days 12 (8–14) 12 (8–14) 10 (8–14) 13 (10–14) 0.13
SAPS III-score 56 (50–60) 57 (53–64) 54 (49–59) 55 (53–60) 0.25
 < 50, No. (%) 34 (22.4) 15 (22.4) 13 (27.1) 6 (16.2) 0.53
 50–59, No. (%) 75 (44.7) 31 (46.3) 25 (52.1) 19 (51.4) 0.76
 ≥ 60, No. (%) 43 (28.3) 21 (31.3) 10 (20.8) 12 (32.4) 0.41
Invasive Respiratory support, No. (%) 104 (68.4) 50 (74.6) 34 (70.8) 20 (54.1) 0.09
Coagulation, Inflammatory and creatinine tests at baseline
 Fibrin-D-dimer, mg/L FEU 1.5 (0.90–3.9) 1.8 (1.1–8.4) 1.1 (0.7–2.4) 1.3 (0.7–2.9) 0.12
 CRP, mg/L 195 (134–270) 198 (134–268) 203 (151–255) 183 (130–287) 0.81
 Hemoglobin, g/L 129 (118–136) 127 (118–137) 130 (119–137) 127 (113–135) 0.39
 Creatinine, µmol/L 70 (57–88) 74 (61–92) 69 (48–87) 62 (50–74) 0.12
 Platelet count, 109/L 264 (195–339) 255 (183–332) 261 (219–318) 302 (225–391) 0.16
 INR 1.1 (1.0–1.1) 1.1 (1.0–1.1) 1.1 (1.0–1.1) 1.0 (1.0–1.2] 0.89
 APTt, s 26 (24–29) 25 (24–29) 26 (23–27) 27 (25–30) 0.32
 Fibrinogen, g/L 6.7 (5.5–8.0) 6.7 (5.6–7.7) 7.2 (6.4–8.3) 6.7 (5.4–7.7) 0.47
  1. Baseline characteristics of 152 patients admitted to the intensive care unit due to COVID-19 at Södersjukhuset, Stockholm, March 6 to April 30, 2020, by initial dosing strategy with tinzaparin/dalteparin as thromboprophylaxis
  2. Values are medians (interquartile range) unless otherwise indicated. APTt, activated partial thromboplastin time; BMI, body mass index; CRP, C-reactive protein; ICU, intensive care unit; OD, once a day; INR, Prothrombin Time International Normalized Ratio; SAPS III, Simplified Acute Physiology Score III
  3. a tinzaparin, 2500–4500 IU OD; or dalteparin, 2500–5000 IU OD
  4. b tinzaparin, > 4500 IU OD to < 175 IU/kg of body weight OD; or dalteparin, > 5000 IU OD to < 200 IU/kg of body weight OD
  5. c tinzaparin, ≥ 175 IU/kg of body weight OD; or dalteparin, ≥ 200 IU/kg of body weight OD
  6. d p-values for differences across exposure categories were obtained using Fisher´s exact test for categorical and Kruskal–Wallis test for continuous data